|Publication number||US6761715 B2|
|Application number||US 10/071,574|
|Publication date||13 Jul 2004|
|Filing date||5 Feb 2002|
|Priority date||26 Apr 2001|
|Also published as||US7458968, US20020161360, US20040220648, WO2002087653A2, WO2002087653A3|
|Publication number||071574, 10071574, US 6761715 B2, US 6761715B2, US-B2-6761715, US6761715 B2, US6761715B2|
|Inventors||Ronald J. Carroll|
|Original Assignee||Ronald J. Carroll|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (33), Non-Patent Citations (4), Referenced by (98), Classifications (20), Legal Events (12)|
|External Links: USPTO, USPTO Assignment, Espacenet|
This application claims the benefit of U. S. Provisional Application Ser. No. 60/286,636, filed Apr. 26, 2001.
This invention relates generally to cryoanalgesia and more particularly to devices and procedures for applying cryoanalgesia to the neuroaxis.
Management of acute and chronic pain has been a concern for as long as medicine has been practiced. Many methods of inducing analgesia and anesthesia have been developed. The use of chemical substances is perhaps the most common approach to pain relief. This approach requires suitable substances that are effective, safe to humans, and do not cause complications or abnormal reactions. Despite the great advances that have been made in the field of anesthesiology, and in the field of pain relief in general, there are still some drawbacks to chemical-based approaches. For instance, the anesthetics generally available today must be administered in carefully graduated doses to assure the patient's well being, require extended periods of fasting prior to treatment, and are often accompanied by undesirable after effects such as nausea.
An alternate approach that avoids these drawbacks is cryoanalgesia, which is a safe and effective approach to providing prolonged pain relief without the complications or undesirable after effects often experienced with chemical-based approaches. As used herein, the term “cryoanalgesia” refers to cooling or freezing of neuronal tissue (nerves, synapses, ganglia, etc.) to produce analgesia or anesthesia. Attempts to use tissue cooling or freezing to control pain have been known since antiquity. Surgery using cold packs and the painless amputation of frozen limbs during wartime are part of military medical history. In the nineteenth century, attempts were made to use tissue cooling to treat a wide range of maladies. Twentieth century studies have shown that the cooling or freezing of neuronal tissue reduces or eliminates pain by interrupting nerve conduction. Cooling neuronal tissue to temperatures in the range of zero to −4 degrees centigrade, and sometimes below, causes analgesia lasting from days to weeks. Neuronal tissues cease functioning when sufficiently cooled, but before becoming frozen. Freezing neuronal tissue (i.e., reducing tissue temperature to −4 to −20 degrees centigrade or below) causes profound long lasting, usually permanent but sometimes reversible, anesthesia of the innervated part. There may well be different outcomes of cooling and freezing, depending on whether the treatment is applied to neuronal axons or neuronal cell bodies (containing the nucleus).
A number of devices for the controlled cooling and/or freezing of small volumes of tissue are available. Rigid cryoprobes exist for percutaneous use or in open invasive surgical procedures. For example, cryoprobes are used for freezing a range of lesions from prostate tissue to metastatic cancers in liver. Neuronal tissue has been frozen with such devices for the relief of pain. Such devices have been in use for more than 20 years.
Cryocatheters or cryogenic catheters are of more recent evolution and have been used by way of the blood vascular route to destroy, by freezing, conducting tissues in the heart for the correction of cardiac arrhythmia. Such cyrocatheters are not designed for cryoanalgesia.
In both these types of systems, coolant gases under pressure are delivered to the tip of the instrument (i.e., the probe or catheter) where expansion of the gas is used to create temperatures as low as −60 degrees centigrade or below which cools or freezes the tissues in the local area around the tip. The size and configuration of the lesion created will depend in large part on a configuration of the tip. The effect obtained will depend upon the rate of cooling, degree of cooling, and the duration of cooling, as well as specifics of the tissue and environment.
While conventional cryoprobes used to treat neuronal tissue can produce excellent results, they generally can be used only for certain percutaneous procedures in which the target neuronal tissue is readily accessible by the rigid probes or for open surgical procedures. These restrictions greatly limit the opportunities for using cryoanalgesia. Accordingly, it would be desirable to have a device and method that would allow a more extensive use of cryoanalgesia.
The above-mentioned need is met by the present invention, which provides a catheter including a catheter body having a proximate end and a distal end, means for holding the distal end adjacent to a neuroaxis structure target, and means for internally delivering a coolant fluid to the distal end of the catheter body. In one possible embodiment, the catheter body is a tube having first and second chambers formed therein. The means for holding includes an expandable portion formed in the tube and a pressurized fluid source connected to the first chamber for inflating the expandable portion, and the means for internally delivering a coolant fluid includes a delivery tube disposed in the second chamber and a source of coolant fluid connected to the delivery tube. A temperature detector can be disposed on an external surface of the catheter body.
The present invention can also include an electrically conductive tip member formed on an external surface of the catheter body, an external electrode for application to a patient's body, and a monitoring/stimulating device electrically connected to the tip member and to the external electrode. The device is capable of delivering an electrical stimulus to the external electrode and measuring sensory evoked potentials in response to input from the tip member.
In use, the distal end of the catheter is inserted into the subarachnoid space of a patient and positioned adjacent to a neuronal tissue target. A portion of the catheter is inflated to hold the distal end in position on the target neuronal tissue. The external electrode is placed on a dermatome on the patient that corresponds to the neuronal tissue target. The monitoring/stimulating device can then be used to deliver an electrical stimulus to the dermatome (which will be transmitted centrally over sensory afferent nerve fibers) and measure resultant sensory evoked potentials detected at the tip member. Measurement of sensory evoked potentials can be used to verify that the distal end is properly positioned relative to the neuronal tissue target, since coolant fluid is delivered into the catheter so as to effect cooling or freezing of the neuronal tissue target and stop neuronal nerve conduction.
The present invention and its advantages over the prior art will become apparent upon reading the following detailed description and the appended claims with reference to the accompanying drawings.
The subject matter that is regarded as the invention is particularly pointed out and distinctly claimed in the concluding part of the specification. The invention, however, may be best understood by reference to the following description taken in conjunction with the accompanying drawing figures in which:
FIG. 1 is a longitudinal cross-sectional view of an introducer from a neuro-cryocatheter system of the present invention.
FIG. 2 is a longitudinal cross-sectional view of cryocatheter from a neuro-cryocatheter system of the present invention.
FIG. 3 is an axial cross-sectional view of the cryocatheter of FIG. 2.
FIGS. 4A-4C are schematic views of the cryocatheter showing a means for angling a distal tip portion of the cryocatheter.
FIG. 5 is a schematic view of a circuit for measuring sensory evoked potentials in a patient.
FIG. 6 is a dorsal view, in partial cutaway, of a portion of a spinal cord.
FIG. 7 is a composite schematic diagram showing the relationship between a spinal cord segment and its corresponding dermatome.
FIG. 8 is an enlarged dorsal view of the spinal cord of FIG. 6 showing the distal end of a cryocatheter located adjacent to a set of dorsal root filaments.
FIG. 9A is a partial dorsal view of a human body showing its dermatomes.
FIG. 9B is a partial ventral view of a human body showing its dermatomes.
The highly structured neuroaxis (the spinal cord and spinal nerves) lends itself to cryoanalgesia techniques to produce analgesia or anesthesia of body parts innervated by the target nerve tissue. This is accomplished by selective cooling or freezing of the target neuronal tissue using a neurocryocatheter system to induce lesions along the neuroaxis. The neuro-cryocatheter system is used to diagnose, monitor and interfere with nerve conduction along the spinal cord axis by invading the cerebrospinal fluid canal (subarachnoid space) by way of percutaneous puncture. The cooling or freezing of neuronal tissue produces analgesia or anesthesia (i.e., “cryoanalgesia”) by impairing nerve conduction of the targeted neuronal tissue. The neuro-cryocatheter system of the present invention may be used not only on human patients but on other animals, particularly vertebrates, as well.
Generally referring to FIGS. 6 and 7 (which are discussed in more detail below), a basic discussion of neuroaxis anatomy is provided to facilitate understanding of the present invention. The human spinal cord is functionally segmented along its length, giving rise to 30 pairs of spinal nerves. The skin is likewise segmented into dermatomes (see FIGS. 9A and 9B). A dermatome is an area of skin contributing sensory afferent nerve fibers to a corresponding spinal cord segment. There is substantial (85%) correspondence between the enervation of skin dermatomes and cord segments. The skin (and deeper structures) and the spinal cord are connected by neurons (primary sensory or afferent neurons) which have sensory receptor endings, including pain receptors in the skin (and deeper structures). The bodies of the primary sensory nerves are found in the dorsal root ganglion, just inside the dural lining of the spinal canal. When sensory nerves are stimulated, a nerve impulse travels over the primary neuron, entering the spinal cord at the corresponding segment by way of the dorsal root nerve filaments. The neuron that transmits the impulse connects the dermatome to its corresponding spinal cord segment. These filaments are longitudinally arranged along the cord as shown in FIG. 6. In the aggregate, these filaments combined are called a dorsal root. The axons of sensory neurons terminate on secondary nerve cell bodies (gray matter) found in the dorsal horn of the spinal cord itself.
The ventral horn of the spinal cord is composed of neuronal bodies of nerves providing enervation of muscles. The axons of motor neurons leave the spinal cord becoming the ventral nerve root filaments. The ventral nerve root filaments and the dorsal nerve filaments are separated by the denticulate ligaments. Just lateral to the dorsal nerve ganglion, the ventral nerve filaments join to form a mixed nerve that travels to the periphery of the body. Mixed nerves therefore carry sensory nerve impulses into the cord and motor nerve impulses away from the cord. Impairing nerve conduction in a mixed nerve impairs both sensory and motor function. Impairing ventral nerve filaments alone impairs only motor function. Impairing dorsal nerve filaments alone impairs only sensory function.
Neurons are composed of cell bodies (nerve bodies) and appendages (axons and dendrites). Cell bodies contain the cell nucleus and other structures essential for the life of the neuron. Axons are extensions of the neuronal cell body of variable length (sometimes a meter long) that conduct electrochemical nerve impulses from the skin (and deeper structures) sensory receptors to the spinal cord where, after entering the cord they synapse on secondary nerve bodies found in the dorsal horn. Axons in the aggregate form nerve filaments. The nerve bodies of the primary sensory neurons are found in the dorsal ganglion. The dorsal ganglion is a collection of nerve bodies found just inside the dura, lateral to the spinal cord and proximal to the formation of the mixed spinal nerve. It should be stressed that the dorsal nerve filaments are formed of aggregates of the axons of the sensory nerves coming from specific dermatomes (and related deeper structures) and going to specific segments of the spinal cord.
Individual axons are within a fine tube of connective tissue called the endoneureon. If axons are destroyed, they will regenerate over time (weeks to months) and resume functioning, as long as the endoneureon tube remains intact, and the nerve cell body remains intact. Freezing axons destroys them, but leaves the endoneureon intact. Freezing nerve cell bodies irreversibly destroys the nerve by killing the cell body. Axons cannot regenerate if the cell body is destroyed. Cooling cell bodies or axons to about 0-20 degrees centigrade causes a reversible cessation of nerve transmission. (See: A. Vania Apkarian et al., A Cryogenic Device for Reversibly Blocking Transmission Through Small Regions of the Spinal Cord White Matter, Journal of Neuroscience Methods, 29 (1989) pp. 93-106, and Linqiu Zhou et al., Mechanism Research of Cryoanalgesia, Neurological Research, Vol. 17, August 1995, pp. 307-311.) This interruption in function may last for minutes to hours.
In one embodiment, the present invention provides prolonged relief of pain through selection of appropriate neuronal targets and freezing those targets to temperatures that result in prolonged impairment of neuronal function. Dorsal root nerve filaments are appropriate targets for such relief of chronic pain. Candidate dermatomes and corresponding dorsal nerve root filaments are determined by the clinical pain pattern.
Referring to the drawings wherein identical reference numerals denote the same elements throughout the various views, FIGS. 1-4 show a neuro-cryocatheter system for the cooling or freezing of neuroaxis structure targets. The system includes an introducer 10 shown in FIG. 1. The introducer 10 comprises a stylet 12 encased by a sheath 14. The stylet 12 has a sharp, pointed tip 16 capable of penetrating soft tissue overlying the spinal canal. Once the introducer 10 has been inserted into the desired location, the stylet 12 is removed and the sheath 14 is left in place to function as a cannula. Preferably, the introducer 10 has an outer diameter of about 1.5 millimeters or less and a length of typically 4-5 inches.
FIGS. 2 and 3 show a cryocatheter 18 for insertion into the sheath 14 after the sheath 14 has been positioned in the patient's body. The cryocatheter 18 has a diameter small enough to fit into the sheath 14 and has a length of about 6-36 inches. The cryocatheter 18 includes a catheter body 20 in the form of a hollow outer tube having a distal end 22 that is insertable through the positioned sheath 14 and a proximate end 24 that remains outside of the body. Although the outer tube 20 is shown as having a circular cross-section, it should be noted that the present invention is not so limited and the cryocatheter 18 can have a variety of configurations. The catheter body or outer tube 20 is made of a non-rigid material and is thermally insulated with a coating 26 of insulating material. A septum 28 is formed inside the outer tube 20 and extends the length thereof to divide the tube interior into first and second chambers 30 and 32. When the cryocatheter 18 is in use, the section thereof encompassing the first chamber 30 will correspond to the dorsal or posterior side of the cryocatheter 18, and the section encompassing the second chamber 32 will correspond to the ventral or anterior side of the cryocatheter 18. The cryocatheter 18 thus has a dorsal side 34 and a ventral side 36. The cryocatheter 18 is preferably made, at least in part, of a material suitable for radiologic imaging.
The outer tube 20 has an expandable portion 37 formed at the distal end 22, on the dorsal side 34 so as to be in fluid communication with the first chamber 30. The expandable portion 37 comprises a section of expandable material formed in the outer tube 20. The remainder of the outer tube 20 is made of a material that is not expandable, or at least not as expandable as the material of the expandable portion 37. A pressurized fluid source 38 is connected with the first chamber 30 via a valve 40. The valve 40 can be operated to allow pressurized fluid from the source 38 to flow into the first chamber 30 and inflate the expandable portion 37 so that the distal end 22 is larger in cross-section than the rest of the outer tube 20. The valve 40 can also be operated to allow pressurized fluid to escape from the first chamber 30 so that the expandable portion 37 deflates.
The outer tube 20 includes a tip member 42 formed on the external surface of the ventral side 36, at the distal end 22. The tip member 42 is made of an electrically conducting material and is not thermally insulated. That is, the coating 26 does not cover the tip member 42. A coolant delivery tube 44 is disposed in the second chamber 32, preferably coaxial therewith. One or more expansion openings 45 are formed in the distal end of the coolant delivery tube 44, which is located adjacent to the distal end 22 of the outer tube 20 and the tip member 42. The proximate end of the coolant delivery tube 44 is connected to a source of pressurized coolant fluid (gas or liquid) 46 via another valve 48. The pressurized coolant fluid flows, under control of the valve 48, down the coolant delivery tube 44 and exits through the expansion opening(s) 45 into the second chamber 32. The coolant fluid expands and cools as it is discharged through the expansion opening(s) 45. Thus, the temperature of the non-insulated tip member 42 will be greatly reduced in a controllable manner such that neuronal tissue in contact with or adjacent to the tip member 42 will be cooled or frozen. The spent coolant fluid flows back through the second chamber 32 and exits through the proximate end 24 in a manner known in the art.
It should be noted that the present invention is not limited to a catheter body comprising a single tube separated into two chambers by a septum. Another possible configuration includes a catheter body formed from two catheters joined together lengthwise. One of the catheters would be an expandable catheter corresponding to the dorsal side 34; the other catheter would be a cryocatheter corresponding to the ventral side 36.
The geometry of the tip member 42 will be determined based on the location and nature of the anatomic target site to be treated, which are discussed in more detail below. Generally, the tip member 42 has a substantially semi-cylindrical shape, as shown in FIG. 2. The length, L, of the tip member 42 (FIG. 3) will be dependent on the anatomic target site to be treated. For example, given the arrangement of afferent filaments entering the dorsal horn (i.e., filaments may enter over several centimeters of the cord for a single nerve), the tip member length would be approximately equal to this length if the nerve filaments are the target. If the target were a dorsal ganglion, a shorter, smaller diameter tip member 42 would be desirable. If the entire posterior cord were to be treated, a longer tip member would be used. If generalized cooling of a substantial part or segment of the cord itself is desired (as to induce spinal anesthesia), then the tip member 42 would be configured to accommodate that objective.
A temperature detector 50 is located on the external surface of the tip member 42. The temperature detector 50, which can be any suitable device such as a thermocouple, can be used to provide feedback, via electric wire 51 connected to an external temperature monitoring device 52, of the tip member temperature during a treatment procedure so that the flow of coolant fluid can be controlled accordingly to obtain the desired temperature.
The cryocatheter 18 optionally includes a hollow conduit 54 disposed inside the second chamber 32 of the outer tube 20, adjacent to the coolant delivery tube 44. The hollow conduit 54 has a distal needle tip 56 and is movable longitudinally within the outer tube 20 by a rotatable head 58 located outside of the tube 20 and attached to the proximate end of the hollow conduit 54. The needle tip 56 can be extended beyond the distal end 22 (as shown in FIG. 3) or retracted back into the outer tube 20 by turning the rotatable head 58 in the appropriate direction. The head 58 can be calibrated so as to indicate how much the needle tip 56 is extended. With the needle tip 56 extended, the hollow conduit 54 can be used for local injections of pharmaceuticals. The hollow conduit 54 could be used diagnostically to verify the proper location of the distal end 22. That is, once the distal end 22 was believed to be located at the desired target site, a small dose of an analgesic drug could be injected via the hollow conduit 54. If the patient experienced pain relief in the affected part, this would indicate that the distal end 22 and the tip member 42 are properly located. As an alternative embodiment, it is possible to use a catheter tip configured to deliver pharmaceuticals in gel form.
In addition, the cryocatheter 18 optionally includes a means for changing the angle of a distal tip portion 59 of the cryocatheter 18 relative to the rest of the cryocatheter 18. One possible tip angle changing means is illustrated schematically in FIGS. 4A-4C. In this arrangement, two guide wires 60 a and 60 b are disposed inside the outer tube 20 on diametrically opposing sides thereof. As seen in FIG. 2, the guide wires 60 a and 60 b are located adjacent to the opposing sides of the septum 28 so as to provide for lateral adjustment of the tip angle. The distal end of each guide wire 60 a and 60 b is fixedly attached to the distal tip portion 59 of the outer tube 20. A first rotatable head 62 a is located outside of the tube 20 and is attached to the proximal end of the first guide wire 60 a, and a second rotatable head 62 b is located outside of the tube 20 and is attached to the proximal end of the second guide wire 60 b. The first and second rotatable heads 62 a and 62 b are rotatively mounted to a handle (not shown) and have first and second levers 64 a and 64 b, respectively, formed thereon. The levers 64 a and 64 b are positioned such that a user holding the handle can manipulate the levers 64 a and 64 b independently to turn the corresponding rotatable head 62 a and 62 b. Turning the first and second heads 62 a and 62 b in the appropriate direction will pull the corresponding guide wire 60 a and 60 b relative to the outer tube 20. Because the far end of each guide wire 60 a and 60 b is fixedly attached to the distal tip portion 59, pulling one of the guide wires 60 a and 60 b causes the distal tip portion 59 to bend relative to the rest of the outer tube 20. (The catheter structures are all made of a flexible material.) Specifically, pulling the first guide wire 60 a causes the distal tip portion 59 to bend to the left as shown in FIG. 4B, while pulling the second guide wire 60 b causes the distal tip portion 59 to bend to the right as shown in FIG. 4C. The rotatable heads 62 a and 62 b are calibrated so that the tip angle can be accurately controlled. Adjusting the tip angle permits the tip member 42 to be positioned adjacent to a wider range of neuroaxis targets.
As mentioned above, the tip member 42 is electrically conducting and can thus function as an electrode for electrodiagnostic purposes. This is accomplished using sensory evoked potentials, which are central nervous system electrical potentials that have traditionally been measured from scalp electrodes after a stimulus is applied to a peripheral nerve or a dermatome. (A dermatome is an area of skin contributing sensory afferent nerve fibers to a spinal nerve(s); there is an anatomic correspondence between a given dermatome and a given dorsal nerve root.) Because evoked potentials as currently measured are remote from the stimulus and are the result of multiple neuronal interactions, they are small in amplitude and difficult to measure above background noise using conventional equipment.
The electrodiagnostic methods of the present invention are illustrated in FIG. 5, which schematically shows the cryocatheter 18 positioned in a patient's neuroaxis 66. A monitoring/stimulating device 70 is electrically connected to the tip member 42 (functioning as an electrode) via a first electrical lead 72 that passes through the cryocatheter 18. An external electrode 74 is applied to the exterior of the patient's body, on the dermatome that corresponds to the desired neuronal target site in the neuroaxis. The external electrode 74 is electrically connected to the monitoring/stimulating device 70 via a second electrical lead 76. The monitoring/stimulating device 70 is capable of generating an electrical stimulus for stimulating nerve endings of a dermatome. The monitoring/stimulating device 70 is also capable of receiving signals from the tip member 42 and measuring and displaying evoked potentials in response to such signals. Many devices for measuring and displaying evoked potentials are commercially available. The monitoring/stimulating device 70 can be any device suitable for such use, including commercially available devices, except that the device 70 will be used with the tip member 42 as the detecting electrode instead of a conventional scalp electrode.
When the tip member 42 is believed to be located at the desired target site in the neuroaxis, a measured electrical stimulus is applied to the corresponding dermatome via the external electrode 74. This electrical stimulus will be conducted centrally by the corresponding sensory (afferent) nerve 68, including the target neuronal tissue, to the spinal cord. If the tip member 42 is in contact with the appropriate target neuronal tissue, an electrical circuit will be completed. That is, the electrical stimulus will be conducted from the monitoring/stimulating device 70 to the external electrode 74 via the second electrical lead 76, from the external electrode 74 to the tip member 42 via the sensory (afferent) nerve 68, and from the tip member 42 to the monitoring/stimulating device 70 via the first electrical lead 72. The monitoring/stimulating device 70 thus provides detection of the dermatomal sensory evoked potential when the tip member 42 is properly located. The design of the cryocatheter 18, which provides for direct contact of the tip member 42 with the target neuronal tissue (as opposed to an electrode on the patient's scalp), greatly enhances the magnitude, sensitivity and specificity of the dermatomal sensory evoked potential.
When the device 70 detects a sensory evoked potential, this serves as an indication that the tip member 42 is properly positioned. At this point, the cooling/freezing treatment of the target site can be carried out. As the target neuronal tissue is cooled, nerve conduction will be interrupted (before freezing) and thereby eliminate or reduce pain. Moreover, nerve conduction interruption will also result in cessation of the sensory evoked potential. Thus, induced functional impairment of the target neuronal tissue will be confirmed when the device 70 ceases to measure a sensory evoked potential. This further verifies that the tip member 42 has been properly positioned and means that protracted cooling or freezing can be carried out to complete the procedure.
As mentioned above, the neuro-cryocatheter system provides cryoanalgesia by cooling or freezing of neuroaxis structure targets. Cooling mixed nerves produces a nerve conduction block wherein motor function is affected before sensory function. Selection of sensory, dorsal nerve structures as targets for cooling/freezing will render this irrelevant. The motor function is in the ventral nerve root, separated from the dorsal root by the denticulate ligament. Large myelinated sensory (afferent) fibers are affected and cease conduction before unmyelinated fibers. Small diameter myelinated fibers appear to be the most sensitive to cold. The most common neuronal tissue associated with pain is a small diameter unmyelinated fiber in the dorsal root.
When cooling neuronal tissue, the nerve conduction block is complete above 0 degrees centigrade, but prolonged conduction disturbances occur only by achieving temperatures of −5 to −20 degrees centigrade. At temperatures between −5 and −20 degrees centigrade neuropraxis may occur without neuronal destruction. Freezing generally occurs at temperatures below −20 degrees centigrade. Once freezing has occurred, no benefit is obtained by achieving by lower temperatures. There is little inflammatory response to freezing and if tissue structures (for example, the endoneurium) are not disrupted, nerve regeneration is possible. Recovery from freezing is accomplished in cases where axon destruction is followed by axonal regeneration. This process of regeneration has been studied and reported in medical literature.
In operation, cryocatheter 18 is introduced into the subarachnoid space of the spinal canal (dorsal aspect) by percutaneous spinal canal puncture. Specifically, after skin preparation, the introducer 10 is inserted into the subarachnoid space at the desired location, and the stylet 12 is removed, leaving the sheath 14 in place to function as a cannula. The structure of the meninges is such that the subarachnoid space can be entered posteriorly, by percutaneous puncture between the spinous processes. The distal end 22 of the cryocatheter 18 is inserted through the sheath 14 and into the subarachnoid space on the dorsal side of the spinal cord. The cryocatheter 18 is oriented such that the expandable portion 37 faces the dorsal dura mater and the tip member 42 faces the dorsal side of the spinal cord.
The distal end 22, and hence the tip member 42, are advanced to the target neuronal tissue. Proper positioning of the distal end 22 can be accomplished with imaging guidance. For instance, providing the cryocatheter 18 with a radio-opaqueness allows the distal end 22 to be placed adjacent to the target neuronal tissue with the aid of radiological imaging. The cryocatheter 18 could also be made of non-magnetic (non-polarizable) material for use in an open MRI device. The external electrode 74 is placed on the patient's body, on the dermatome that corresponds to the target neuronal tissue, and the device 70 is turned on such that the electrodiagnostic function of the cryocatheter 18 is operating.
There are many possible neuroaxis structure targets that could be selected for cooling or freezing with cryocatheter 18. Referring to FIG. 6, which is a dorsal view of a portion of a spinal cord 78 with the arachnoid mater 80 and the dura mater 82 shown pulled back, and FIG. 7, which is a composite diagram of a spinal cord segment and its corresponding dermatome, the basic structure of the neuroaxis and its possible targets will be described. The spinal cord 78 is comprised of the interior gray matter 84 and the white matter 86, which encompasses the gray matter 84. The gray matter 84 includes two ventral horns 88 and two dorsal horns 90. The arachnoid mater 80 completely surrounds the spinal cord 78, and the dura mater 82 surrounds the arachnoid mater 80. The subarachnoid space 91, several millimeters in depth and filled with spinal fluid, lies between the spinal cord 78 and the arachnoid mater 80. There are 30 paired spinal nerves 92 emanating from the spinal cord (8 cervical, 12 thoracic, 5 lumbar, 5 sacral), three of which are shown in FIG. 6 and one in FIG. 7 (shown extending through a vertebrae 93). Each spinal nerve 92 is divided into dorsal root filaments 94 and ventral root filaments 96 within the subarachnoid space 91. The dorsal root filaments 94, which are composed of sensory nerve fibers, enter the dorsal horn 90 of the spinal cord 78. The ventral root filaments 96, which are composed of motor nerve elements, emanate from the ventral horn 88. The anatomic separation is accentuated by the denticulate ligament 98, which lies between the dorsal root filaments 94 and the ventral root filaments 96. The nerve root filaments are made up of nerve axons. The nerve root filaments 94 and 96 are represented by single axons in FIG. 7. Dorsal axons extend to the dermatome 99 that corresponds to the respective spinal cord segment, as shown in FIG. 7. Ventral axons extend to a corresponding muscle (not shown). The dorsal root ganglia 100 (represented by a single nerve cell body in FIG. 7), which lie lateral of the dorsal root filaments 94 in the subarachnoid space 91, contain the neuronal bodies of most of the afferent nerve axons. With the exception of the head, the dorsal root filaments 94 of the paired spinal nerves 92 supply the major sensory input of the body.
Accordingly, the dorsal root filaments 94 are a primary target for cooling or freezing. Because these are sensory nerve structures, interrupting conduction by cooling or freezing will reduce or eliminate pain that would otherwise be transmitted by the nerve structures. The ventral root elements 96 (which are separated from the dorsal root elements by the denticulate ligament) are concerned with motor function and generally are not targets for the relief of pain. Other possible targets include the dorsal root ganglia 100, which contain the neuronal cell bodies of the dorsal root elements, and the dorsal horn 90 (particularly Rexed levels 1-4, or even Rexed levels 1-5). Lissauer's tract, which is adjacent to the dorsal horn 90, is also a potential target for cooling or freezing.
Visceral afferent nerve fibers conducting pain signals also enter the spinal cord via the dorsal roots. By rendering the dorsal root neuronal elements or the dorsal horn non-functional (non-conductive) along the cord at various levels both visceral and peripheral nerve sensory afferents can be controlled. It should therefore be possible to alleviate pain in viscera by cooling or freezing the appropriate spinal targets. For example, pancreatic pain could be alleviated this way.
As mentioned above, the distal end 22 of the cryocatheter 18 is inserted into the subarachnoid space and advanced until the tip member 42 is adjacent to the target neuronal tissue. For example, the distal end 22 is schematically shown as being adjacent to a set of dorsal root filaments 94 in FIG. 6. FIG. 8 shows the location of the distal end 22 relative to the dorsal root filaments 94 in more detail. With the tip member 42 believed to be properly positioned adjacent to the target tissue, the dorsal expandable portion 37 of the cryocatheter 18 is inflated with pressurized fluid from the source 38, as controlled by the valve 40, until it expands into contact with the arachnoid mater 80 and the adjacent dura mater 82 and presses the tip member 42 on the ventral surface of the cryocatheter 18 into contact with the dorsal neuronal target. Thus, inflation of the expandable portion 37 holds the distal end 22 in position relative to the target neuronal tissue. As discussed above, reception of dermatomal sensory evoked potentials by the device 70 indicates that the tip member 42 is properly positioned.
Once the tip member 42 is fixed in the proper position, the valve 48 is opened to admit a flow of coolant fluid to the coolant delivery tube 44. The coolant fluid exits the tube 44 via the opening(s) 45, expands, and thereby cools the tip member 42. The temperature of the tip member 42 is monitored by the temperature detector 50. By monitoring the tip member temperature, the operator will be able to control the flow of coolant fluid so as to gradually cool the tip member 42, and hence the neuronal target tissue. Functional impairment of the target neuronal tissue induced by cooling or freezing will be confirmed by cessation of the dermatomal evoked sensory potential measured by the device 70.
Depending on the goals of the procedure, the neuronal tissue will be cooled or frozen. If cooled, the procedure may be carried out for extended periods of time. If neuronal tissue is frozen, continued application of the freezing process beyond that necessary to achieve at least −20 degrees centigrade is unnecessary.
If the cryocatheter 18 is being used for diagnostic purposes only (i.e., being used to determine the functional status of neuronal tissue), the procedure is the same as that described above except that the cooling/freezing steps are omitted and the diagnostic information would be obtained by measuring dermatomal sensory evoked potentials off the neuronal tissue while stimulating the appropriate dermatome. For example, the use of this function could maintain spinal cord function during neurosurgery.
The affect of cooling or freezing of neuroaxis tissue will be impacted by the particular anatomic site chosen (the target neuronal tissue), the rate of cooling or freezing, the temperature achieved, the duration of cooling in some circumstances, and thawing/freezing cycles, if employed. (Thawing/freezing cycles refers to small ice crystals thawing and the water being subsequently refrozen by larger ice crystals.) Freezing results in the withdrawing of water from biologic systems and the deposition of water in ice crystals. The development of ice crystals depends upon a) crystal nucleation rate and b) the ice crystal growth rate. Both of these factors are dependent on temperature and the rate of cooling. These factors are also tissue type specific and may not be linear with fall in temperature. The location of the ice crystals (i.e., intracellular versus extracellular) is dependent on the rate of cooling, with rapid freezing promoting the formation of intracellular ice crystals and increasing the risk of ultimate cell death. The size of the crystals for a given amount of water (in tissue) is a function of the number of crystals initiated by the process. The rate of temperature fall may well be a dominant variable. This in turn will be a function of efficiency by which a system removes heat. Anatomic considerations, such as blood vessel supply (blood flow) and cerebrospinal flow rates, may well impact the cooling rate. Recrystallization (i.e., the growth of large crystals at the expense of smaller ones) will influence the final nature and the extent of tissue damage and may occur during thawing. Thawing/freezing cycles, if employed, will impact the final lesion.
When the rate of cooling is slow, ice crystal nucleation occurs in the extracellular space drawing water out of the cell. The result is a formation of a few large, generally extracellular, crystals. The further result is such as to leave the cell membrane largely intact; membrane rupture is uncommon. This is useful when freezing nerve axons, leaving the endoneurium intact which allows for axonal regeneration. Extracellular ice crystal formation is unlikely to cause cell death even if the cell body is cooled or frozen. Freezing of vascular tissue that results in ischemia of the end-organ tissue may also be a factor in the destruction of the cell within the ice ball. However, the vascular supply of the spinal cord appears diffuse with multiple collaterals such that ischemia may not be a problem.
The geometry of the tip member 42 is a factor in lesion production since the tissue immediately adjacent to the tip member 42 will freeze more quickly and thoroughly. Moreover, the size of the ice ball, a field of cooling gradients, is correlated to the tip geometry. This could result in intracellular ice near the tip member 42 and extracellular ice away from the tip member 42. In any event, it is anticipated that there will be a freezing gradient related to the tip member 42 and its configuration.
Neuronal cell death (as opposed to axonal disruption) is likely to occur when a critical temperature achieved. This is believed to be −4 degrees centigrade or below and certainly is reached at −20 degrees centigrade. This temperature may be somewhat tissue dependent (for example, red blood cell versus neuronal tissue). There are reports of neuronal recovery for temperatures as low as −15 degrees centigrade. However, there appears to be a consensus that cells do not survive at temperatures lower than −20 degrees centigrade. Neuronal generation and conduction of nerve electropotentials ceases during cooling, but before nerve tissue is frozen. In addition, the electrical impedance of the tip member 42 goes up as ice is formed on it. Controlled cooling of the tip member 42 and the target tissue can avoid this and allow sensory evoked potential measurement.
An up to two hour exposure of neuronal tissue to cold temperature (e.g., between +5 and −5 degrees centigrade) will cool but not freeze the tissue and produce transient interruption of nerve conduction lasting hours or even days. When a mixed nerve is cooled, motor function is affected before sensory function. However, as previously noted, cooling the dorsal root or horn and the posterior cord itself should impact sensory function alone and not motor function. When neuronal cell bodies are frozen to −20 degrees centigrade or below, the duration of freezing becomes irrelevant because of the likelihood of cell death occurring.
If axons or nerve bodies are cooled, the return of function will return relatively quickly (i.e., over the course of many hours to several days). If axons are frozen, return of function will take many days or weeks as degeneration/regeneration of axons occur (axonal tissue regenerates at approximately 1-3 millimeters per day). If nerve bodies are frozen, neuronal function will generally not return. Accordingly, the target tissue should be selected carefully.
An alternative embodiment to the neuro-cryocatheter system described above would be to provide the cryogenic, electrodiagnostic, and pharmaceutical delivery functions with two or more catheters rather than a single catheter. Such an alternative system would include an introducer the same as or similar to the introducer 10 of FIG. 1 and a plurality of catheters. For instance, there could be a cryocatheter having cryogenic capabilities for cooling or freezing of neuroaxis structure targets and a separate catheter for delivering pharmaceuticals. There could also be another catheter having an electrode like the tip member 42 but no cryogenic capability. Such a catheter would be used for diagnostic purposes only (i.e., for determining the functional status of neuronal tissue).
While specific embodiments of the present invention have been described, it will be apparent to those skilled in the art that various modifications thereto can be made without departing from the spirit and scope of the invention as defined in the appended claims.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US3901241||31 May 1973||26 Aug 1975||Al Corp Du||Disposable cryosurgical instrument|
|US4202336||3 Jan 1978||13 May 1980||Erbe Elektromedizin Kg||Cauterizing probes for cryosurgery|
|US4306561||5 Nov 1979||22 Dec 1981||Ocean Trading Co., Ltd.||Holding apparatus for repairing severed nerves and method of using the same|
|US4646735||4 Oct 1985||3 Mar 1987||Seney John S||Pain-alleviating tissue treatment assembly|
|US4802475||22 Jun 1987||7 Feb 1989||Weshahy Ahmed H A G||Methods and apparatus of applying intra-lesional cryotherapy|
|US4904237 *||16 May 1988||27 Feb 1990||Janese Woodrow W||Apparatus for the exchange of cerebrospinal fluid and a method of treating brain and spinal cord injuries|
|US4936306||27 Nov 1985||26 Jun 1990||Doty James R||Device and method for monitoring evoked potentials and electroencephalograms|
|US5081990||11 May 1990||21 Jan 1992||New York University||Catheter for spinal epidural injection of drugs and measurement of evoked potentials|
|US5147355||23 Sep 1988||15 Sep 1992||Brigham And Womens Hospital||Cryoablation catheter and method of performing cryoablation|
|US5281213||16 Apr 1992||25 Jan 1994||Implemed, Inc.||Catheter for ice mapping and ablation|
|US5281215||15 Jun 1992||25 Jan 1994||Implemed, Inc.||Cryogenic catheter|
|US5314423||3 Nov 1992||24 May 1994||Seney John S||Cold electrode pain alleviating tissue treatment assembly|
|US5336176 *||15 Apr 1992||9 Aug 1994||Inbae Yoon||Automatic retractable safety penetrating instrument|
|US5417686||21 Dec 1992||23 May 1995||The Texas A&M University System||Temperature control mechanisms for a micro heat pipe catheter|
|US5423770 *||22 Jun 1993||13 Jun 1995||Yoon; Inbae||Automatic retractable safety penetrating instrument|
|US5423807||24 Jan 1994||13 Jun 1995||Implemed, Inc.||Cryogenic mapping and ablation catheter|
|US5591162 *||21 Mar 1994||7 Jan 1997||The Texas A&M University System||Treatment method using a micro heat pipe catheter|
|US5672172||6 Jun 1995||30 Sep 1997||Vros Corporation||Surgical instrument with ultrasound pulse generator|
|US5693077||1 Feb 1996||2 Dec 1997||Friedman; Mark H.||Treatment of vascular and tension headache atypical facial pain allergic rhinitis and cervical muscle hyperactivity|
|US5741248||7 Jun 1995||21 Apr 1998||Temple University-Of The Commonwealth System Of Higher Education||Fluorochemical liquid augmented cryosurgery|
|US5957963||24 Mar 1998||28 Sep 1999||Del Mar Medical Technologies, Inc.||Selective organ hypothermia method and apparatus|
|US6051019||23 Jan 1998||18 Apr 2000||Del Mar Medical Technologies, Inc.||Selective organ hypothermia method and apparatus|
|US6106517||24 Sep 1997||22 Aug 2000||Situs Corporation||Surgical instrument with ultrasound pulse generator|
|US6190370 *||24 Jul 1998||20 Feb 2001||Arrow International, Inc.||Devices, systems and methods for determining proper placement of epidural catheters|
|US6217552 *||7 Apr 1999||17 Apr 2001||Coaxia, Inc.||Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma|
|US6254599||22 Mar 1999||3 Jul 2001||Atrionix, Inc.||Circumferential ablation device assembly|
|US6272370 *||7 Aug 1998||7 Aug 2001||The Regents Of University Of Minnesota||MR-visible medical device for neurological interventions using nonlinear magnetic stereotaxis and a method imaging|
|US6364899 *||9 Jun 1999||2 Apr 2002||Innercool Therapies, Inc.||Heat pipe nerve cooler|
|US6379331 *||29 Mar 2001||30 Apr 2002||Coaxia, Inc.||Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma|
|US6551349 *||22 Mar 2001||22 Apr 2003||Innercool Therapies, Inc.||Selective organ cooling apparatus|
|US20030014016 *||13 Jul 2001||16 Jan 2003||Purdy Phillip D.||Methods and apparatuses for navigating the subaracnhnoid space|
|US20030130651 *||27 Dec 2002||10 Jul 2003||Lennox Charles D.||Uniform selective cerebral hypothermia|
|EP0043447A2||4 Jun 1981||13 Jan 1982||Karl-Heinz Kreibel||Low-temperature transmission device for medical purposes|
|1||A. Vania Apkarian, et al., A cryogenic device for reversibly blocking transmission through small regions of the spinal cord white matter, Journal of Neuroscience Methods, Feb. 1989, p. 93-106, 29, Elsevier Science Publishers B.V. (Biomedical Division), Syracuse, NY.|
|2||Francis Robiscsek, MD, et al, Biological thersholds of cold-induced phrenic nerve injury, The Journal of Thoracic and Cardiovascular Surgery, Jan. 1990, p. 167-170, vol. 99 No. 1.|
|3||Linqui Zhou, et al., Mechanism research of cryoanalgesia, Neurological Research, Aug. 1995, p. 307-311, vol. 17, Forefront Publishing Group.|
|4||P. J. D. Evans, Cryoanalgesia, The application of low temperatures to nerves to produce anesthesia or analgesia, Anesthesia, 1981, vol. 36, pp. 1003-1013.|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US7455666 *||13 Jul 2001||25 Nov 2008||Board Of Regents, The University Of Texas System||Methods and apparatuses for navigating the subarachnoid space|
|US7458968 *||28 May 2004||2 Dec 2008||Carroll Ronald J||Device for neurocryo analgesia and anesthesia|
|US7662177||12 Apr 2006||16 Feb 2010||Bacoustics, Llc||Apparatus and methods for pain relief using ultrasound waves in combination with cryogenic energy|
|US7713266||5 Dec 2005||11 May 2010||Myoscience, Inc.||Subdermal cryogenic remodeling of muscles, nerves, connective tissue, and/or adipose tissue (fat)|
|US7787954||25 Nov 2008||31 Aug 2010||Board Of Regents, The University Of Texas System||Methods and apparatuses for navigating the subaracnhnoid space|
|US7850683||28 Jun 2007||14 Dec 2010||Myoscience, Inc.||Subdermal cryogenic remodeling of muscles, nerves, connective tissue, and/or adipose tissue (fat)|
|US7862558||6 Mar 2009||4 Jan 2011||Myoscience, Inc.||Subdermal cryogenic remodeling of muscles, nerves, connective tissue, and/or adipose tissue (fat)|
|US7938822||12 May 2010||10 May 2011||Icecure Medical Ltd.||Heating and cooling of cryosurgical instrument using a single cryogen|
|US7967814||5 Feb 2010||28 Jun 2011||Icecure Medical Ltd.||Cryoprobe with vibrating mechanism|
|US7967815||25 Mar 2010||28 Jun 2011||Icecure Medical Ltd.||Cryosurgical instrument with enhanced heat transfer|
|US7998137||12 Apr 2010||16 Aug 2011||Myoscience, Inc.||Subdermal cryogenic remodeling of muscles, nerves, connective tissue, and/or adipose tissue (fat)|
|US8048069||13 Apr 2007||1 Nov 2011||Medtronic, Inc.||User interface for ablation therapy|
|US8080005||29 Jul 2010||20 Dec 2011||Icecure Medical Ltd.||Closed loop cryosurgical pressure and flow regulated system|
|US8083733||13 Apr 2009||27 Dec 2011||Icecure Medical Ltd.||Cryosurgical instrument with enhanced heat exchange|
|US8131353||31 Aug 2010||6 Mar 2012||Board Of Regents, The University Of Texas System||Methods and apparatuses for navigating the subarachnoid space|
|US8160695||18 Jun 2008||17 Apr 2012||The Invention Science Fund I, Llc||System for chemical modulation of neural activity|
|US8162812||12 Mar 2010||24 Apr 2012||Icecure Medical Ltd.||Combined cryotherapy and brachytherapy device and method|
|US8165668||15 Feb 2008||24 Apr 2012||The Invention Science Fund I, Llc||Method for magnetic modulation of neural conduction|
|US8165669||15 Feb 2008||24 Apr 2012||The Invention Science Fund I, Llc||System for magnetic modulation of neural conduction|
|US8170658||15 Feb 2008||1 May 2012||The Invention Science Fund I, Llc||System for electrical modulation of neural conduction|
|US8170659||4 Apr 2008||1 May 2012||The Invention Science Fund I, Llc||Method for thermal modulation of neural activity|
|US8170660||4 Apr 2008||1 May 2012||The Invention Science Fund I, Llc||System for thermal modulation of neural activity|
|US8180446||5 Dec 2007||15 May 2012||The Invention Science Fund I, Llc||Method and system for cyclical neural modulation based on activity state|
|US8180447||18 Jun 2008||15 May 2012||The Invention Science Fund I, Llc||Method for reversible chemical modulation of neural activity|
|US8195287||15 Feb 2008||5 Jun 2012||The Invention Science Fund I, Llc||Method for electrical modulation of neural conduction|
|US8233976||18 Jun 2008||31 Jul 2012||The Invention Science Fund I, Llc||System for transdermal chemical modulation of neural activity|
|US8255057||29 Jan 2009||28 Aug 2012||Nevro Corporation||Systems and methods for producing asynchronous neural responses to treat pain and/or other patient conditions|
|US8298216||14 Nov 2008||30 Oct 2012||Myoscience, Inc.||Pain management using cryogenic remodeling|
|US8409185||16 Feb 2007||2 Apr 2013||Myoscience, Inc.||Replaceable and/or easily removable needle systems for dermal and transdermal cryogenic remodeling|
|US8509906||9 Jul 2012||13 Aug 2013||Nevro Corporation||Systems and methods for producing asynchronous neural responses to treat pain and/or other patient conditions|
|US8630706||13 Mar 2012||14 Jan 2014||The Invention Science Fund I, Llc||Method and system for reversible chemical modulation of neural activity|
|US8676322||22 Jan 2009||18 Mar 2014||Boston Scientific Neuromodulation Corporation||Methods and systems of treating pancreatitis pain|
|US8715275||13 Sep 2012||6 May 2014||Myoscience, Inc.||Pain management using cryogenic remodeling|
|US8758337||1 Sep 2011||24 Jun 2014||Medtronic, Inc.||User interface for ablation therapy|
|US8801664||4 Feb 2009||12 Aug 2014||Robert J. Perry||Medical procedure kit|
|US8814856||30 Apr 2007||26 Aug 2014||Medtronic, Inc.||Extension and retraction mechanism for a hand-held device|
|US8849410||5 Apr 2013||30 Sep 2014||Nevro Corporation||Systems and methods for producing asynchronous neural responses to treat pain and/or other patient conditions|
|US8880167 *||13 Feb 2013||4 Nov 2014||Flint Hills Scientific, Llc||Selective recruitment and activation of fiber types in nerves for the control of undesirable brain state changes|
|US8914112||22 Jan 2009||16 Dec 2014||Boston Scienctific Neuromodulation Corporation||Methods and systems of treating pancreatitis pain caused by sphincter of Oddi dysfunction|
|US8945114||26 Apr 2007||3 Feb 2015||Medtronic, Inc.||Fluid sensor for ablation therapy|
|US8961452||6 Mar 2012||24 Feb 2015||Board Of Regents, The University Of Texas System||Multi-sheath member apparatus|
|US8989858||18 Jun 2008||24 Mar 2015||The Invention Science Fund I, Llc||Implant system for chemical modulation of neural activity|
|US9014802||9 Dec 2013||21 Apr 2015||The Invention Science Fund I, Llc||Method and system for modulating neural activity in a limb|
|US9017318||22 Jan 2013||28 Apr 2015||Myoscience, Inc.||Cryogenic probe system and method|
|US9020591||9 Dec 2013||28 Apr 2015||The Invention Science Fund I, Llc||Method and system for ultrasonic neural modulation in a limb|
|US9020592||9 Dec 2013||28 Apr 2015||The Invention Science Fund I, Llc||Method and system for blocking nerve conduction|
|US9023022||15 Mar 2013||5 May 2015||Warsaw Orthopedic, Inc.||Nerve and soft tissue ablation device having release instrument|
|US9023023||15 Mar 2013||5 May 2015||Warsaw Orthopedic, Inc.||Nerve and soft tissue ablation device|
|US9033966||15 Mar 2013||19 May 2015||Warsaw Orthopedic, Inc.||Nerve and soft tissue ablation device|
|US9066712||22 Dec 2009||30 Jun 2015||Myoscience, Inc.||Integrated cryosurgical system with refrigerant and electrical power source|
|US9072498||17 Nov 2010||7 Jul 2015||Myoscience, Inc.||Subdermal cryogenic remodeling of muscles, nerves, connective tissue, and/or adipose tissue (fat)|
|US9101346||30 Sep 2013||11 Aug 2015||Myoscience, Inc.||Pain management using cryogenic remodeling|
|US9113855||5 Mar 2013||25 Aug 2015||Myoscience, Inc.||Replaceable and/or easily removable needle systems for dermal and transdermal cryogenic remodeling|
|US9131975||15 Mar 2013||15 Sep 2015||Warsaw Orthopedic, Inc.||Nerve and soft tissue ablation device|
|US9155584||14 Jan 2013||13 Oct 2015||Myoscience, Inc.||Cryogenic probe filtration system|
|US9186197||15 Mar 2013||17 Nov 2015||Warsaw Orthopedic, Inc.||Nerve and soft tissue ablation device for treating pain|
|US9186207||14 Jun 2007||17 Nov 2015||Medtronic, Inc.||Distal viewing window of a medical catheter|
|US9198707||15 Mar 2013||1 Dec 2015||Warsaw Orthopedic, Inc.||Nerve and soft tissue ablation device and method|
|US9241753||14 Jan 2013||26 Jan 2016||Myoscience, Inc.||Skin protection for subdermal cryogenic remodeling for cosmetic and other treatments|
|US9241754||15 Mar 2013||26 Jan 2016||Warsaw Orthopedic, Inc.||Nerve and soft tissue ablation device|
|US9254162||21 Dec 2006||9 Feb 2016||Myoscience, Inc.||Dermal and transdermal cryogenic microprobe systems|
|US9295512||12 Sep 2013||29 Mar 2016||Myoscience, Inc.||Methods and devices for pain management|
|US9314290||14 Jan 2013||19 Apr 2016||Myoscience, Inc.||Cryogenic needle with freeze zone regulation|
|US9320559||4 May 2015||26 Apr 2016||Warsaw Orthopedic, Inc.||Nerve and soft tissue ablation device having release instrument|
|US9345526||7 Jul 2011||24 May 2016||Myoscience, Inc.||Subdermal cryogenic remodeling of muscles, nerves, connective tissue, and/or adipose tissue (fat)|
|US9358374||10 Apr 2015||7 Jun 2016||Gearbox, Llc||Method and system for blocking nerve conduction|
|US9403013||10 Sep 2014||2 Aug 2016||Nevro Corporation|
|US9579508 *||3 Nov 2014||28 Feb 2017||Ivan Osorio||Selective recruitment and activation of fiber types in nerves for the control of undesirable brain state changes|
|US9597480||6 Oct 2015||21 Mar 2017||Endophys Holding, LLC||Intraluminal devices and systems|
|US9610112||18 Mar 2014||4 Apr 2017||Myoscience, Inc.||Cryogenic enhancement of joint function, alleviation of joint stiffness and/or alleviation of pain associated with osteoarthritis|
|US9668800||18 Mar 2014||6 Jun 2017||Myoscience, Inc.||Methods and systems for treatment of spasticity|
|US9788773||15 Mar 2013||17 Oct 2017||Robert J. Perry||Vein presentation enhancement device|
|US9789315||6 Jun 2016||17 Oct 2017||Gearbox, Llc||Method and system for modulating neural activity|
|US20030014016 *||13 Jul 2001||16 Jan 2003||Purdy Phillip D.||Methods and apparatuses for navigating the subaracnhnoid space|
|US20040215181 *||25 Apr 2003||28 Oct 2004||Medtronic, Inc.||Delivery of fluid during transurethral prostate treatment|
|US20040220648 *||28 May 2004||4 Nov 2004||Carroll Ronald J.||Device for neurocryo analgesia and anesthesia|
|US20070073354 *||26 Sep 2005||29 Mar 2007||Knudson Mark B||Neural blocking therapy|
|US20070129714 *||5 Dec 2005||7 Jun 2007||Echo Healthcare Llc||Subdermal cryogenic remodeling of muscles, nerves, connective tissue, and/or adipose tissue (FAT)|
|US20070179491 *||31 Jan 2006||2 Aug 2007||Medtronic, Inc.||Sensing needle for ablation therapy|
|US20080082145 *||13 Apr 2007||3 Apr 2008||Medtronic, Inc.||User interface for ablation therapy|
|US20080183164 *||28 Jun 2007||31 Jul 2008||Myoscience, Inc.||Subdermal cryogenic remodeling of muscles, nerves, connective tissue, and/or adipose tissue (fat)|
|US20080269737 *||26 Apr 2007||30 Oct 2008||Medtronic, Inc.||Fluid sensor for ablation therapy|
|US20080269862 *||30 Apr 2007||30 Oct 2008||Medtronic, Inc.||Extension and retraction mechanism for a hand-held device|
|US20080275440 *||3 May 2007||6 Nov 2008||Medtronic, Inc.||Post-ablation verification of lesion size|
|US20080312497 *||14 Jun 2007||18 Dec 2008||Medtronic, Inc.||Distal viewing window of a medical catheter|
|US20090076357 *||25 Nov 2008||19 Mar 2009||Purdy Phillip D||Methods and Apparatuses for Navigating the Subaracnhnoid Space|
|US20090149911 *||15 Feb 2008||11 Jun 2009||Searete Llc, A Limited Liability Corporation Of The State Of Delaware||System for electrical modulation of neural conduction|
|US20090149912 *||15 Feb 2008||11 Jun 2009||Searete Llc, A Limited Liability Corporation Of The State Of Delaware||Method for electrical modulation of neural conduction|
|US20090149919 *||4 Apr 2008||11 Jun 2009||Searete Llc, A Limited Liability Corporation Of The State Of Delaware||Method for thermal modulation of neural activity|
|US20090171334 *||6 Mar 2009||2 Jul 2009||Myoscience, Inc.||Subdermal cryogenic remodeling of muscles, nerves, connective tissue, and/or adipose tissue (fat)|
|US20090192557 *||22 Jan 2009||30 Jul 2009||Whitehurst Todd K||Methods and systems of treating pancreatitis pain caused by sphincter of oddi dysfunction|
|US20090192558 *||22 Jan 2009||30 Jul 2009||Whitehurst Todd K||Methods and systems of treating pancreatitis pain|
|US20090248001 *||14 Nov 2008||1 Oct 2009||Myoscience, Inc.||Pain management using cryogenic remodeling|
|US20090299357 *||2 Apr 2007||3 Dec 2009||Thomas Jefferson University||Cryoneedle and cryotheraphy system|
|US20100198207 *||12 Apr 2010||5 Aug 2010||Myoscience, Inc.||Subdermal cryogenic remodeling of muscles, nerves, connective tissue, and/or adipose tissue (fat)|
|US20100324397 *||31 Aug 2010||23 Dec 2010||Purdy Phillip D||Methods and Apparatuses for Navigating the Subaracnhnoid Space|
|US20110144631 *||17 Nov 2010||16 Jun 2011||Myoscience, Inc.||Subdermal cryogenic remodeling of muscles, nerves, connective tissue, and/or adipose tissue (fat)|
|US20150051637 *||3 Nov 2014||19 Feb 2015||Ivan Osorio||Selective recruitment and activation of fiber types in nerves for the control of undesirable brain state changes|
|U.S. Classification||606/21, 128/898|
|International Classification||A61B17/00, A61B5/05, A61N1/05, A61B18/02, A61B17/22, A61B5/04|
|Cooperative Classification||A61B5/05, A61B2018/0212, A61B2017/00039, A61B5/04, A61B2018/0262, A61B2017/22051, A61B18/02, A61B2018/0022, A61N1/0551, A61B2017/00084, A61B5/4893|
|11 Aug 2003||AS||Assignment|
Owner name: APPLIED CRYONEUROLOGICS LLC, MAINE
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CARROLL, RONALD J.;REEL/FRAME:014368/0933
Effective date: 20030805
|14 Jan 2008||FPAY||Fee payment|
Year of fee payment: 4
|21 Jan 2008||REMI||Maintenance fee reminder mailed|
|12 Jan 2012||FPAY||Fee payment|
Year of fee payment: 8
|19 Feb 2016||REMI||Maintenance fee reminder mailed|
|29 Feb 2016||AS||Assignment|
Owner name: CARROLL, SEAN, CALIFORNIA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CARROLL, RONALD J.;REEL/FRAME:037850/0318
Effective date: 20160213
|13 Jul 2016||REIN||Reinstatement after maintenance fee payment confirmed|
|13 Jul 2016||LAPS||Lapse for failure to pay maintenance fees|
|30 Aug 2016||FP||Expired due to failure to pay maintenance fee|
Effective date: 20160713
|12 Sep 2016||PRDP||Patent reinstated due to the acceptance of a late maintenance fee|
Effective date: 20160915
|15 Sep 2016||FPAY||Fee payment|
Year of fee payment: 12
|15 Sep 2016||SULP||Surcharge for late payment|